Company / R&D per Share
Aurinia Pharmaceuticals Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.23
FY2025
5-year range
$0.14 / $0.47
FY2021-FY2025
Trend
+59.7%
vs FY2024
Sector context
#189 of 208
Health Care
What the data says
Among 208 Health Care companies, Aurinia Pharmaceuticals Inc. is in the bottom 9% for r&d per share. R&D per Share returned to growth in FY2025 after 4 years of decline, reaching $0.23.
Based on SEC 10-K filings.
0.23 in FY2025 with a 5-year CAGR of -17.1%.
Declined from $0.35 to $0.23 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -16.6%
- 5-Year CAGR
- -17.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 208This company $0.23 Sector average $12.19
▼
-98.1% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 59.7% year-over-year.
- Ranks #189 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2024.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.23 | +59.7% |
| FY2024 | $0.14 | -58.8% |
| FY2023 | $0.35 | -11.7% |
| FY2022 | $0.40 | -16.0% |
| FY2021 | $0.47 | -19.7% |
| FY2020 | $0.59 | +3.6% |
| FY2019 | $0.57 | +16.4% |
| FY2018 | $0.49 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026